Clinical Study Protocol M16-178 A Randomized, Controlled, Multicenter, Open Label Study with Blinded Assessment of the Efficacy
![Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal](https://mednexus.org/cms/10.1097/CM9.0000000000001163/asset/0d9c1936-dd27-41e4-a0b3-60f7fb670d90/assets/graphic/0366-6999-133-22-005-f005.png)
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal
![PDF) Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis PDF) Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis](https://www.researchgate.net/publication/346241969/figure/tbl1/AS:983816244060161@1611571479425/Demographic-and-disease-characteristics-of-patient-at-Baseline_Q320.jpg)
PDF) Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
![Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal](https://mednexus.org/cms/10.1097/CM9.0000000000001163/asset/e701c908-224f-4809-8e11-d66be0414d76/assets/graphic/0366-6999-133-22-005-f001.png)
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal
![PDF) Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis PDF) Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis](https://i1.rgstatic.net/publication/346241969_Secukinumab_demonstrates_high_efficacy_and_a_favorable_safety_profile_over_52_weeks_in_Chinese_patients_with_moderate_to_severe_plaque_psoriasis/links/600e8706299bf14088bc7cef/largepreview.png)